ストックスクリーナーアプリを入手
8.96
3.94%
0.34
アフターアワーズ：
8.92
-0.04
-0.45%
前日終値:
$8.62
開ける：
$8.62
24時間の取引高:
2.08M
Relative Volume:
0.85
時価総額：
$885.48M
収益：
-
当期純損益:
$-44.84M
株価収益率:
-19.06
EPS:
-0.47
ネットキャッシュフロー:
$-44.23M
1週間 パフォーマンス:
-1.65%
1か月 パフォーマンス:
-10.85%
6か月 パフォーマンス:
-35.86%
1年 パフォーマンス:
-39.13%
1日の値動き範囲:
$8.4517
$8.98
1週間の範囲:
$8.4517
$9.655
52週間の値動き範囲:
$8.4517
$18.90
Ars Pharmaceuticals Inc Stock (SPRY) Company Profile
名前
Ars Pharmaceuticals Inc
セクター
電話
858-771-9307
住所
11682 EL CAMINO REAL, SUITE 120, SAN DIEGO
SPRY を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SPRY
Ars Pharmaceuticals Inc
|
8.96 | 851.88M | 0 | -44.84M | -44.23M | -0.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 398.11M | -1.03B | -868.57M | -5.7032 |
Ars Pharmaceuticals Inc Stock (SPRY) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-09-04 | 開始されました | Roth Capital | Buy |
| 2025-03-07 | 開始されました | Scotiabank | Sector Outperform |
| 2025-02-10 | 開始されました | Oppenheimer | Outperform |
| 2024-08-20 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-08-13 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2024-08-12 | 繰り返されました | Leerink Partners | Outperform |
| 2024-07-25 | 開始されました | Raymond James | Outperform |
| 2024-03-05 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-02-20 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2023-09-20 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2023-01-31 | 開始されました | Wedbush | Outperform |
| 2023-01-03 | 開始されました | William Blair | Outperform |
| 2022-12-13 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Ars Pharmaceuticals Inc (SPRY) 最新ニュース
ARS Pharmaceuticals (NASDAQ:SPRY) Hits New 52-Week LowWhat's Next? - MarketBeat
How ARS Pharmaceuticals Inc. stock valuations compare to rivalsWeekly Stock Recap & Low Drawdown Investment Ideas - newser.com
Reversal indicators forming on ARS Pharmaceuticals Inc. stockWeekly Stock Summary & High Accuracy Investment Entry Signals - newser.com
How ARS Pharmaceuticals Inc. stock reacts to inflationary pressures2025 EndofYear Setup & Community Consensus Stock Picks - newser.com
How ARS Pharmaceuticals Inc. stock trades during market volatilityJuly 2025 Update & Trade Opportunity Analysis - newser.com
Why ARS Pharmaceuticals Inc. stock could rally in 2025July 2025 Intraday Action & Daily Volume Surge Trade Alerts - newser.com
Why ARS Pharmaceuticals Inc. stock could outperform in 2025Fed Meeting & Safe Capital Allocation Plans - newser.com
Will ARS Pharmaceuticals Inc. rebound enough to break evenPortfolio Value Report & Low Drawdown Trading Strategies - newser.com
Multi factor analysis applied to ARS Pharmaceuticals Inc.July 2025 Highlights & Expert Approved Momentum Ideas - newser.com
Trend analysis for ARS Pharmaceuticals Inc. this week2025 Sector Review & Stock Portfolio Risk Control - newser.com
Why ARS Pharmaceuticals Inc. stock is recommended by analystsWeekly Risk Summary & Growth Focused Stock Reports - newser.com
Is ARS Pharmaceuticals Inc. stock supported by innovation pipelineJuly 2025 Catalysts & Community Trade Idea Sharing Platform - newser.com
Is ARS Pharmaceuticals Inc. a candidate for recovery playWeekly Stock Report & AI Forecasted Entry/Exit Points - newser.com
Ars Pharmaceuticals’ Latest Study: A Potential Game-Changer in Allergy Treatment - MSN
Can ARS Pharmaceuticals Inc. stock sustain revenue growthWeekly Stock Summary & Daily Risk Controlled Trade Plans - Fundação Cultural do Pará
Custom strategy builders for tracking ARS Pharmaceuticals Inc.Weekly Profit Report & Accurate Buy Signal Notifications - newser.com
Allianz Asset Management GmbH Makes New $639,000 Investment in ARS Pharmaceuticals, Inc. $SPRY - MarketBeat
How ARS Pharmaceuticals Inc. stock performs in rate cut cycles2025 Trading Recap & Fast Entry Momentum Trade Alerts - Fundação Cultural do Pará
Ars Pharmaceuticals’ Promising Study on ARS-2 for Chronic Urticaria: What Investors Need to Know - TipRanks
ARS Pharmaceuticals Hits New 52-Week Low at $9.08 Amid Financial Struggles - Markets Mojo
What analysts say about ARS Pharmaceuticals Inc stockPrice Momentum Alerts & Free Gain Edge With Data - earlytimes.in
Ars Pharmaceuticals Inc (SPRY) 財務データ
収益
当期純利益
現金流量
EPS
1.62%
0.21%
大文字化:
|
ボリューム (24 時間):